Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Report summarizes breast cancer study findings from A. Gennari and co-researchers
February 26th, 2009
"In the past decade, a considerable effort has been made to Identify molecular markers that predict anthracycline activity. A number of retrospective studies that evaluated the clinical activity of anthracyclines according to HER2 status suggested that the additional benefit of these agents, as compared with non-anthracycline-based chemotherapy, is confined to HER2-positive tumors," scientists in Genoa, Italy report. "More recently, 2 meta-analyses, based on abstracted data, have reinforced this concept, challenging the use of adjuvant anthracyclines in patients with HER2-negative tumors. Additional data suggested that patients who derive the largest clinical benefit...
Source: Women's Health Weekly (2009-02-26)
|
